The results in Fig. 3A, B showed that pitavastatin reduced HFD or FFA-induced CD36 expression in tumor tissues or cells, indicating that pitavastatin-reduced cancer development may be regulated by CD36. This evidence concerns the gene CD36 and neoplasm.